Cannabidiol - Zynerba Pharmaceuticals

Drug Profile

Cannabidiol - Zynerba Pharmaceuticals

Alternative Names: Cannabidiol gel patch; Cannabidiol transdermal gel; CBD; CBD gel patch; CBD transdermal gel; Synthetic CBD; Topical cannabidiol gel; Topical CBD gel; Transdermal CBD gel; ZYN002

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy; Fragile X syndrome; Osteoarthritis
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 14 Nov 2017 Zynerba Pharmaceuticals plans a meeting with the US FDA to discuss study results of ZYN 002 for Fragile X syndrome and Osteoarthritisin the first quarter of 2018
  • 14 Nov 2017 Zynerba Pharmaceuticals plans a pivotal trial programme for Fragile X syndrome in the first half of 2018
  • 14 Nov 2017 Zynerba plans a pivotal phase II/III trial for Osteoarthritis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top